AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21119151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for personality disorders (CBT-PD)
Number of subjects: 106
Study 21119151 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study 19066155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti6A17Nb-alloy (girotan L)
Number of subjects: 10
Study 19066155 — intervention group
Group type: COMPARATOR
Intervention: CoCr-alloy (remanium GM 800+)
Number of subjects: 10
Study 16647419 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human arylsulfatase B (rhASB)
Number of subjects: 39
Study 16647419 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 14604568 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, 15 microg of each protein given at first and second injection (4 weeks apart)
Number of subjects: 120
Study 14604568 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, No sulphadoxine-pyrimethamine (SP)
Number of subjects: 120
Study 14604568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant emulsified with saline) with No sulphadoxine-pyrimethamine (SP)
Number of subjects: 120
Study 14604568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant emulsified with saline) with SP
Number of subjects: 120
Study 14604568 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+vaccine
Number of subjects: 120
Study 10824625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (steady-state concentrations)
Number of subjects: 16
Study 10824625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10824625 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 16
Study 8880558 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure measured by automatic sphygmomanometer
Number of subjects: 56
Study 8880558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical BP measurements by male observers
Number of subjects: 56
Study 8880558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical BP measurements by female observers
Number of subjects: 56
Study 8880558 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated BP measurements
Number of subjects: 56
Study 1738925 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-treated patients
Number of subjects: 411
Study 1738925 — intervention group
Group type: COMPARATOR
Intervention: Non-CsA-treated patients
Number of subjects: 411
Study 6392168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 65
Study 6392168 — intervention group
Group type: COMPARATOR
Intervention: Renografin-76
Number of subjects: 65
Study 30961557 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp support messages (60 messages over 3 months)
Number of subjects: 132
Study 30961557 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 132
Study 30265039 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for attending treatment for 6 weeks
Number of subjects: 360
Study 30265039 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for attending treatment for 7-12 weeks
Number of subjects: 360
Study 30265039 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve weeks of attendance CM
Number of subjects: 360
Study 30265039 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 360
Study 30265039 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance-based CM
Number of subjects: 360
Study 27184989 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 441
Study 25187211 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum of seven sessions of multidimensional, person‐centred care by HIV nurses trained in palliative care over a period of 5 months
Number of subjects: 120
Study 25187211 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 120
Study 22662730 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, telephone‐based, cognitive‐behavioral self‐management intervention
Number of subjects: 0
Study 22662730 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18685891 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker Exercise
Number of subjects: 11
Study 18685891 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing therapy
Number of subjects: 11
Study 17443366 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical conditioning program targeting axial and extremity flexibility, coordination, and speed of movement.
Number of subjects: 178
Study 17443366 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving home, environment safety modules.
Number of subjects: 178
Study 16365239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-laparoscopic cholecystectomy (M-LC)
Number of subjects: 79
Study 16365239 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (C-LC)
Number of subjects: 79
Study 11952542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate at a dose of 10 mg kg(‐1) daily up to 600 mg day(‐1)
Number of subjects: 80
Study 11952542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 80
Study 9861126 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 150
Study 9861126 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1.25 mg
Number of subjects: 150
Study 9861126 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg with Droperidol 1.25 mg
Number of subjects: 150
Study 7624737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 6 g daily (6 enterosoluble tablets of 500 mg AA, twice a day)
Number of subjects: 24
Study 7624737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tartaric acid, TA) 2.55 g daily (213 mg TA, twice a day)
Number of subjects: 24
Study 2151405 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.2 mg monthly for 6 months)
Number of subjects: 21
Study 2151405 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms daily for 6 months)
Number of subjects: 21
Study 360561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1,000 mg. twice daily
Number of subjects: 28
Study 360561 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 500 mg. four times a day
Number of subjects: 28
Study 31177906 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ETA receptor antagonist, sitaxentan
Number of subjects: 27
Study 31177906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31177906 — intervention group
Group type: COMPARATOR
Intervention: Long-acting nifedipine
Number of subjects: 27
Study 28655128 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping along with conventional treatment
Number of subjects: 54
Study 28655128 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 54
Study 26290009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Number of subjects: 1868
Study 26290009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yogurt
Number of subjects: 1868
Study 26290009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-fat yogurt
Number of subjects: 1868
Study 26290009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 1868
Study 26290009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 1868
Study 23063254 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nano-hybrid resin composite (Exite/Tetric EvoCeram)
Number of subjects: 52
Study 23063254 — intervention group
Group type: COMPARATOR
Intervention: Conventional hybrid resin composite (Exite/Tetric Ceram)
Number of subjects: 52
Study 23063254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study 21795455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg metreleptin (n = 11)
Number of subjects: 20
Study 21795455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 20
Study 21795455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01, 0.1, and 0.3 mg/kg metreleptin in both fed and fasting conditions for 1 and 3 d
Number of subjects: 20
Study 19332895 — intervention group
Group type: EXPERIMENTAL
Intervention: Poincaré analysis of arterial oxygen saturation (SaO2) signals
Number of subjects: 117
Study 17453095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of one percent phenol and one percent menthol, twice a day for six weeks
Number of subjects: 80
Study 17453095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15475212 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative tendons
Number of subjects: 3
Study 15475212 — intervention group
Group type: EXPERIMENTAL
Intervention: Contra-lateral healthy tendons of post-operative subjects
Number of subjects: 3
Study 15475212 — intervention group
Group type: COMPARATOR
Intervention: Healthy tendons of control group
Number of subjects: 3
Study 15475212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single traumatic rupture subject
Number of subjects: 3
Study 11212050 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine with naloxone (0.208 microg x kg(‐1) x hr(‐1))
Number of subjects: 43
Study 11212050 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine without naloxone (control group)
Number of subjects: 43
Study 11212050 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine with naloxone
Number of subjects: 43
Study 9506771 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg dexamethasone
Number of subjects: 9
Study 9506771 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg dexamethasone
Number of subjects: 9
Study 9506771 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study 7816418 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg digitoxin per day
Number of subjects: 10
Study 7816418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2904582 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 sessions of intensive dynamic back extensor exercises over three months
Number of subjects: 105
Study 2904582 — intervention group
Group type: COMPARATOR
Intervention: A similar programme at one‐fifth the exercise intensity
Number of subjects: 105
Study 2904582 — intervention group
Group type: COMPARATOR
Intervention: One month of thermotherapy, massage, and mild exercises
Number of subjects: 105
Study 30982223 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin plus CsA
Number of subjects: 20
Study 30982223 — intervention group
Group type: COMPARATOR
Intervention: pravastatin plus placebo
Number of subjects: 20
Study 30982223 — intervention group
Group type: EXPERIMENTAL
Intervention: OATP1B1 c.521T>C genotype
Number of subjects: 20
Study 29187416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention including adherence support for corrective devices, adaptations to the home environment, communication training, and referral to community-based support services.
Number of subjects: 24
Study 29187416 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of implementation of the intervention
Number of subjects: 24
Study 29187416 — intervention group
Group type: EXPERIMENTAL
Intervention: Study procedures including outcome assessment measures
Number of subjects: 24
Study 26939325 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Gaohuang (BL 43)
Number of subjects: 72
Study 26939325 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 72
Study 23465178 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PSA testing and follow-up testing after ERSPC publication
Number of subjects: 0
Study 23465178 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing after a PSA level result of >10 ng/mL
Number of subjects: 0
Study 23465178 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a urologist after a PSA level result of >4 ng/mL
Number of subjects: 0
Study 21349239 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg once daily plus pipamperone 5 mg twice daily (PipCit)
Number of subjects: 165
Study 21349239 — intervention group
Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 165
Study 19916992 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal dose of nelfinavir (1250 mg q12h for 3.5 days)
Number of subjects: 66
Study 19916992 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of nelfinavir (1250 mg q12h for 3 days and single dose of 3125 mg on day 4)
Number of subjects: 66
Study 19916992 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir for *1*2 subjects
Number of subjects: 66
Study 19916992 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir for *2*2 subjects
Number of subjects: 66
Study 19916992 — intervention group
Group type: EXPERIMENTAL
Intervention: Active moiety (nelfinavir + M8) for *1*2 and *2*2 subjects
Number of subjects: 66
Study 17299467 — intervention group
Group type: EXPERIMENTAL
Intervention: Test yoghurt containing GOS (12 g/day), prunes (12 g/day) and linseed (6 g/day)
Number of subjects: 43
Study 17299467 — intervention group
Group type: EXPERIMENTAL
Intervention: Test yoghurt containing GOS, prunes and linseed
Number of subjects: 43
Study 17299467 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt
Number of subjects: 43
Study 14618095 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of amlodipine (5 mg initially, titrated to 10 mg if diastolic BP >= 90 mm Hg)
Number of subjects: 62
Study 14618095 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of amlodipine
Number of subjects: 62
Study 11009051 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-strength grapefruit juice (200 ml)
Number of subjects: 12
Study 11009051 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice (200 ml)
Number of subjects: 12
Study 11009051 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose double-strength grapefruit juice (three times daily)
Number of subjects: 12
Study 9106277 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Visual Field (RVF) stimulation with words at orientations of 0 degrees and 15 degrees
Number of subjects: 0
Study 9106277 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal presentation format
Number of subjects: 0
Study 9106277 — intervention group
Group type: COMPARATOR
Intervention: Other orientations (not specified)
Number of subjects: 0
Study 1395911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 80 mg daily for 3 months)
Number of subjects: 40
Study 2869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 304
Study 2869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 304
Study 2869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg/kg
Number of subjects: 304
Study 2869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 0.5 mg/kg
Number of subjects: 304
Study 2869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.05 mg/kg and 0.08 mg/kg
Number of subjects: 304
Study 2869713 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium vs Pancuronium vs Suxamethonium
Number of subjects: 304
Study 29110109 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based Kellgren and Lawrence (K&L) grading
Number of subjects: 50
Study 26510643 — intervention group
Group type: EXPERIMENTAL
Intervention: VeinViewer
Number of subjects: 53
Study 26510643 — intervention group
Group type: COMPARATOR
Intervention: Standard methods
Number of subjects: 53
Study 24067192 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50, 150, or 300 mg/day)
Number of subjects: 0
Study 24067192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24067192 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (Study 2)
Number of subjects: 0
Study 24067192 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (Study 4)
Number of subjects: 0
Study 24067192 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day (adjunct therapy)
Number of subjects: 0
Study 24067192 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day (adjunct therapy)
Number of subjects: 0
Study 22219462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography after thoracic surgery (SATS)
Number of subjects: 120
Study 20586860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofalcone (300 mg/day)
Number of subjects: 64
Study 20586860 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg/day)
Number of subjects: 64
Study 17825448 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10mg)
Number of subjects: 7
Study 17825448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16046295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 16046295 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 12421996 — intervention group
Group type: EXPERIMENTAL
Intervention: Native high‐molecular‐weight hyaluronan (Artzal)
Number of subjects: 210
Study 12421996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐linked hyaluronan (Synvisc)
Number of subjects: 210
Study 12421996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (Artzal or Synvisc pooled)
Number of subjects: 210
Study 12421996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 10589623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 10589623 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 10589623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (Sevoflurane and Isoflurane)
Number of subjects: 30
Study 8708713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 1.8 mg/kg
Number of subjects: 609
Study 8708713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 2.4 mg/kg
Number of subjects: 609
Study 8708713 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 32 mg
Number of subjects: 609
Study 1935499 — intervention group
Group type: COMPARATOR
Intervention: Potatoes boiled and consumed fresh at 60 degrees C (Experiment A)
Number of subjects: 13
Study 1935499 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes boiled, frozen, thawed and consumed at 20 degrees C (Experiment B)
Number of subjects: 13
Study 1935499 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes boiled, frozen, thawed, reheated to 90 degrees C, and consumed at 60 degrees C (Experiment C)
Number of subjects: 13
Study 6794713 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple procedure
Number of subjects: 100
Study 6794713 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular phenolisation
Number of subjects: 100
Study 30477800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (serum biomarker)
Number of subjects: 5380
Study 30477800 — intervention group
Group type: EXPERIMENTAL
Intervention: All renal biomarkers (including urine biomarkers)
Number of subjects: 5380
Study 30065941 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation (FMS)
Number of subjects: 30
Study 30065941 — intervention group
Group type: COMPARATOR
Intervention: Control group (electrode stimulation at supraspinatus and deltoid muscles)
Number of subjects: 30
Study 26191966 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention plus guideline-level care
Number of subjects: 180
Study 26191966 — intervention group
Group type: COMPARATOR
Intervention: Caregiver reports (ADCS-ADL)
Number of subjects: 180
Study 25481190 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG PSN combined with CO(2) laser
Number of subjects: 102
Study 25481190 — intervention group
Group type: COMPARATOR
Intervention: CO(2) laser
Number of subjects: 102
Study 22101861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based Pain and Palliative Care Service (PPCS)
Number of subjects: 152
Study 22101861 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 152
Study 20203161 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg intravenously
Number of subjects: 15
Study 20203161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17095134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HHS) 2 ml/kg/10 min (7.2% NaCl with 6% hydroxy ethyl starch 200,000/0.5)
Number of subjects: 66
Study 17095134 — intervention group
Group type: COMPARATOR
Intervention: HES alone
Number of subjects: 66
Study 17095134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HHS)
Number of subjects: 66
Study 16307956 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with goal object present
Number of subjects: 60
Study 16307956 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no goal object
Number of subjects: 60
Study 12461393 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential fusion with ALIF Brantigan cage plus posterior instrumentation
Number of subjects: 148
Study 12461393 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion with titanium CD‐Horizon
Number of subjects: 148
Study 10506878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin, 1 g b.i.d.
Number of subjects: 0
Study 10506878 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid, 500 mg x 4/d
Number of subjects: 0
Study 7546418 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 279
Study 7546418 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in beta 2M
Number of subjects: 279
Study 7546418 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring serum immunologic markers
Number of subjects: 279
Study 7546418 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched by baseline CD4 cell count and duration of follow-up)
Number of subjects: 279
Study 1903019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg
Number of subjects: 30